Theratechnologies (THTX) said Wednesday it acquired exclusive Canadian rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals (IONS).
The agreement includes olezarsen, which is being evaluated for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen, which is being studied for hereditary angioedema treatment.
Theratechnologies will pay Ionis $10 million upfront, with potential milestone payments of up to $12.75 million and tiered double-digit royalties on net sales.
The company said it would oversee regulatory approvals in Canada while Ionis would remain the primary manufacturer. The agreement extends until commercialization ceases or upon earlier termination.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。